Mounjaro®
Starting from £179.99/mo
Start journey Learn moreMost people notice Wegovy side effects within the first one to three days after their initial injection, and the gastrointestinal ones — nausea, stomach discomfort, loose stools — tend to peak in the days that follow. For many, symptoms settle within one to two weeks at a given dose, only to return briefly after each dose increase. These medicines are prescription-only, and a prescriber considers your full health picture before recommending one.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Semaglutide works partly by slowing how fast food leaves the stomach, and your body notices that shift almost immediately. The full range of Wegovy side effects is wide, but the gastrointestinal ones dominate early on because GLP-1 receptors are densely expressed in the gut as well as the brain. Within a day or two of the first 0.25 mg dose, many people report feeling fuller than usual, sometimes with a low-level nausea that comes and goes around mealtimes.
A common misconception worth setting aside: the nausea does not mean something is wrong or that your body is rejecting the medicine. It is the expected biological response to a sudden change in gastric motility, and it tends to soften as your system adapts. The titration schedule (moving through doses gradually over several months) exists precisely to give your gut time to adjust. To understand when nausea specifically tends to begin, the pattern is fairly consistent across clinical experience.
According to the NHS medicines page for semaglutide, the most commonly reported early effects are nausea, vomiting, diarrhoea, constipation and stomach pain. Headache, fatigue and dizziness also appear in this early window, though they are generally mild. Injection-site reactions (a small amount of redness or itching at the site) are possible too, typically resolving within a day or two.
The pattern most people describe is a wave: symptoms arrive in the first few days at a new dose, peak around days three to five, then gradually ease over one to two weeks. Once the body has settled at one dose level, the next increase can bring a smaller version of the same wave. This is why Wegovy's titration schedule spaces each increase by roughly four weeks, it is not arbitrary; it is matched to how long adaptation typically takes.
Side effects at the higher maintenance doses (1.7 mg and 2.4 mg) can feel more pronounced than at the 0.25 mg or 0.5 mg starting doses, simply because the effect on gastric emptying is stronger. Eating smaller, lower-fat meals and staying well hydrated are the practical steps most often recommended to reduce intensity, though any changes to how you manage your treatment should be discussed with your prescriber rather than decided in isolation.
For those who want a clearer picture of how soon side effects from Wegovy tend to appear, the short version is that most people find acute discomfort is at its worst in weeks one and two, with a meaningful improvement by week three or four at any given dose. You can also read this page, which looks at the duration question in more detail.
Not all discomfort is the ordinary adjustment response, and some symptoms warrant prompt medical attention. In January 2026, the MHRA issued a Drug Safety Update specifically highlighting acute pancreatitis as an infrequent but serious risk with GLP-1 medicines including semaglutide. The symptom to recognise is severe, persistent stomach pain, the kind that does not ease and may radiate through to the back, sometimes alongside vomiting. That is not something to monitor at home; it needs same-day medical assessment.
Other signs that need prompt attention include: symptoms of significant dehydration (very dark urine, dizziness, minimal urination) from repeated vomiting or diarrhoea; any sign of a serious allergic reaction such as facial swelling, difficulty breathing or a spreading rash; sudden or worsening changes in vision in people with diabetes; and any new or worsening low mood or thoughts of self-harm. If you are unsure whether what you are experiencing falls into the ordinary adjustment category or something more serious, contact your prescriber, call 111, or go to urgent care.
You can report any suspected side effect through the MHRA's Yellow Card scheme, it is open to patients as well as healthcare professionals, and reports genuinely contribute to post-marketing safety monitoring for newer medicines like Wegovy.
No, not everyone does. Some people complete the full titration from 0.25 mg to 2.4 mg with nothing more than occasional mild nausea after eating too quickly. Individual variation is real and not fully predictable; factors like baseline gut sensitivity, diet composition and how closely the injection timing is observed all seem to play a role, though the evidence is largely observational rather than definitive.
People who eat large, high-fat meals shortly after injecting tend to report more intense nausea than those who eat lighter and earlier in the post-injection window. Alcohol can compound gastric discomfort. Timing the injection on a day when you can rest the following morning, if your schedule allows, is something prescribers sometimes suggest during the adjustment phase, though specific advice belongs in your consultation rather than in general copy.
Our prescribers discuss side-effect management, timing and what to expect at each dose stage as a standard part of the consultation. If you are considering Wegovy and want to talk through suitability and what to realistically expect, speaking to our team is a good place to start. You can also read a fuller overview of how Wegovy works and who it is licensed for, or explore what the very first side effects typically look like before your first injection.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.